20,000 Shares in Biogen Inc. $BIIB Acquired by Sivik Global Healthcare LLC

Sivik Global Healthcare LLC purchased a new position in shares of Biogen Inc. (NASDAQ:BIIB) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 20,000 shares of the biotechnology company’s stock, valued at approximately $3,520,000. Biogen accounts for 1.0% of Sivik Global Healthcare LLC’s holdings, making the stock its 29th biggest position.

A number of other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its stake in Biogen by 1.0% during the 2nd quarter. State Street Corp now owns 7,468,807 shares of the biotechnology company’s stock worth $938,007,000 after buying an additional 71,897 shares during the period. Invesco Ltd. increased its position in shares of Biogen by 4.2% during the third quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock worth $338,731,000 after acquiring an additional 98,001 shares in the last quarter. AQR Capital Management LLC increased its position in shares of Biogen by 30.7% during the third quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock worth $248,809,000 after acquiring an additional 418,776 shares in the last quarter. Legal & General Group Plc increased its position in shares of Biogen by 10.1% during the third quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock worth $223,203,000 after acquiring an additional 146,583 shares in the last quarter. Finally, Pacer Advisors Inc. increased its position in shares of Biogen by 9.9% during the third quarter. Pacer Advisors Inc. now owns 1,451,249 shares of the biotechnology company’s stock worth $203,291,000 after acquiring an additional 131,258 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen struck a multi‑target collaboration and license with Alloy Therapeutics to use Alloy’s AntiClastic™ antisense oligonucleotide platform, expanding Biogen’s RNA‑targeting capabilities and pipeline optionality. This partnership is viewed as constructive for longer‑term growth prospects. Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen
• Positive Sentiment: Analyst and media pieces (Yahoo/Zacks) highlight Biogen’s history of beating EPS estimates and argue the company has the setup to potentially beat again next quarter, which supports bullish earnings expectations. Why Biogen (BIIB) Could Beat Earnings Estimates Again
• Neutral Sentiment: RBC lowered its price target from $233 to $213 but kept an Outperform rating — a mixed signal: the firm remains positive on Biogen’s trajectory while trimming near‑term upside expectations. RBC Capital Adjusts Biogen Price Target
• Neutral Sentiment: Coverage noted a possible Biogen-related deal moving Apellis shares (reporting referenced a ~$5.6B transaction). If true, M&A activity would materially affect capital allocation; the report so far is a catalyst but requires confirmation and detail. Apellis Stock Soars After Biogen Deal
• Negative Sentiment: Near‑term headwinds: reports and company disclosures indicate first‑quarter expenses will be higher than previously expected, including an announced ~$34M pre‑tax acquired in‑process R&D/upfront and milestone expense. Elevated Q1 costs have already pressured the stock recently. Biogen Expects 1Q Results Will Include Acquired In-Process R&D Expense of $34M

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on BIIB shares. Wells Fargo & Company boosted their target price on shares of Biogen from $190.00 to $200.00 and gave the stock an “equal weight” rating in a research report on Sunday, February 8th. TD Cowen boosted their target price on shares of Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Tudor Pickering set a $201.00 target price on shares of Biogen in a research report on Monday, February 9th. Wedbush boosted their target price on shares of Biogen from $187.00 to $191.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 1st. Finally, UBS Group started coverage on shares of Biogen in a research report on Tuesday, January 6th. They set a “neutral” rating and a $185.00 target price for the company. Twelve investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $207.54.

Insider Buying and Selling

In related news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.18% of the company’s stock.

Biogen Price Performance

BIIB opened at $175.61 on Wednesday. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03. The company has a market capitalization of $25.77 billion, a price-to-earnings ratio of 19.93, a P/E/G ratio of 2.37 and a beta of 0.16. The firm’s fifty day moving average price is $186.61 and its two-hundred day moving average price is $172.16. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business’s revenue for the quarter was down 7.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.